搜索临床试验以:VB-111 bevacizumab
总计5681个结果
-
Vascular Biogenics Ltd. operating as VBL Therapeutics未知
-
Vascular Biogenics Ltd. operating as VBL Therapeutics完全的
-
Vascular Biogenics Ltd. operating as VBL Therapeutics完全的
-
ViscofanMinisterio de Ciencia e Innovación, Spain未知
-
Vascular Biogenics Ltd. operating as VBL Therapeutics完全的
-
National Cancer Institute (NCI)完全的
-
Vascular Biogenics Ltd. operating as VBL Therapeutics完全的
-
Vascular Biogenics Ltd. operating as VBL TherapeuticsGOG Foundation完全的
-
Galera Therapeutics, Inc.完全的
-
University of North Carolina, Chapel HillBoston Children's Hospital; Medical College of Wisconsin; National Football League邀请报名
-
RANDNational Institute on Minority Health and Health Disparities (NIMHD); Clinical Directors Network招聘中
-
Merrimack Pharmaceuticals终止
-
Massachusetts General Hospital完全的
-
Taisho Pharmaceutical R&D Inc.Yale University完全的
-
Rennes University HospitalÉcole Normale Supérieure de Cachan完全的
-
Vascular Biogenics Ltd. operating as VBL Therapeutics完全的Differential Thyroid Cancer美国
-
Qlaris Bio, Inc.招聘中
-
Gilead Sciences终止
-
Medical University of WarsawWarsaw University of Technology未知
-
NovalGen Ltd.招聘中滤泡性淋巴瘤 | 套细胞淋巴瘤 | 弥漫性大 B 细胞淋巴瘤 | 非小细胞肺癌 (NSCLC) | 小淋巴细胞淋巴瘤 | 恶性黑色素瘤 | 慢性淋巴细胞白血病英国
-
REGENXBIO Inc.主动,不招人
-
Qlaris Bio, Inc.尚未招聘
-
Achieve Life Sciences完全的
-
AbbVie招聘中晚期实体瘤癌症美国, 澳大利亚, 以色列, 日本, 大韩民国, 波多黎各, 西班牙, 台湾, 加拿大, 法国, 比利时
-
Vascular Biogenics Ltd. operating as VBL Therapeutics完全的
-
Veru Inc.完全的
-
Cytosite Biopharma Inc.University of Alabama at Birmingham完全的
-
Ludwig Institute for Cancer ResearchWyeth is now a wholly owned subsidiary of Pfizer终止